Clinical Trials Logo

Peritoneal Neoplasms clinical trials

View clinical trials related to Peritoneal Neoplasms.

Filter by:

NCT ID: NCT02903771 Completed - Ovarian Neoplasms Clinical Trials

Phase I Study of Cantrixil in Patients With Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer.

Start date: November 2016
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to determine the safety and feasibility of weekly intra-peritoneal administration of Cantrixil to women with persistent or recurrent ovarian cancer, Fallopian tube cancer or primary peritoneal cancer. The study also aims to determine the maximum tolerated dose of Cantrixil in these patients when administered as a monotherapy or a combination therapy.

NCT ID: NCT02891447 Completed - Clinical trials for Gastric Adenocarcinoma

Heated Mitomycin and Cisplatin During Surgery in Treating Patients With Stomach or Gastroesophageal Cancer

Start date: September 1, 2016
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well heated mitomycin and cisplatin during surgery work in treating patients with stomach or gastroesophageal cancer. Drugs used in chemotherapy, such as mitomycin and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Heating a chemotherapy solution and infusing it directly into the abdomen may kill more tumor cells.

NCT ID: NCT02865811 Completed - Ovarian Cancer Clinical Trials

Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer

Start date: September 15, 2016
Phase: Phase 2
Study type: Interventional

This research study is studying the combination of Pegylated Liposomal Doxorubicin (PLD) and Pembrolizumab as a possible treatment for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer that is resistant to platinum therapy. The following interventions will be used in this study: - Pegylated liposomal doxorubicin (PLD) - Pembrolizumab

NCT ID: NCT02855944 Completed - Ovarian Cancer Clinical Trials

ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients

Start date: March 1, 2017
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine how patients with ovarian, fallopian tube, and primary peritoneal cancer will best respond to treatment with rucaparib versus chemotherapy.

NCT ID: NCT02833753 Completed - Colorectal Cancer Clinical Trials

Trial of Intraperitoneal (IP) Oxaliplatin in Combination With Intravenous FOLFIRI

Start date: July 2016
Phase: Phase 1
Study type: Interventional

This is a Phase I dose escalation study to determine how much chemotherapy can be safely administered into the abdomen while experiencing the fewest possible side effects.

NCT ID: NCT02823860 Completed - Clinical trials for Digestive Peritoneal Carcinomatosis

Clinical and Biological Digestive Peritoneal Carcinomatosis Data Base From the French National Network of Peritoneal Surface Malignancies

BIG-RENAPE
Start date: February 12, 2016
Phase: N/A
Study type: Interventional

To access to good quality biological samples is a prerequisite for high level translational research. The BIG-RENAPE study has been established by the French hyperthermic intraperitoneal chemotherapy centers involved in the management of peritoneal surface malignancies. The main BIG-RENAPE study aim is to create a large multicentric and prospective repository for biological and tissue samples, which will provide a source of materials for a wide array of health related research studies - BIG-RENAPE Biobank-based research: i) validating known and promising biomarkers; ii) identifying new predictive and prognostic factors; iii) evaluating the impact of current health care strategies; iv) standardizing diagnostic and therapeutic management through guidelines; v) developing new drugs. The BIG-RENAPE Biobank is certified according to NFS 96-900 as a service of processing, storage and transfer of high quality biological (plasma, serum, buffy coat) and tissue (formalin-fixed-paraffin-embedded) samples. Biospecimens are collected at each stage of diagnostic and therapeutic care. The patient and his derivates are anonymized and registered in a national web database reporting disease status, treatments, surgical procedures, pathological diagnosis, quality of life's assessment and long term follow-up. All participants have given their informed consent before any sample. The BIG-RENAPE study was approved by the local Ethical Committee, based on the assessed compliance to French regulatory rules.

NCT ID: NCT02786524 Completed - Ovarian Neoplasms Clinical Trials

Effect of Outpatient Symptom Management on Gynecologic Oncology Patients Receiving Chemotherapy

Start date: February 15, 2016
Phase: N/A
Study type: Interventional

To evaluate whether formal referral to The Symptom Management and Supportive Care Clinic improves symptom burden in advanced stage or recurrent gynecologic oncology chemotherapy patients compared with symptom management performed by the primary gynecologic oncologist.

NCT ID: NCT02784028 Completed - Clinical trials for Peritoneal Carcinomatosis

Study in Patients With Peritoneal Carcinomatosis From CEA Overexpressing Digestive Cancer

FLUOCAR-1
Start date: December 2014
Phase: N/A
Study type: Interventional

The digestive cancer is the second cause of death worldwide. The presence of peritoneal carcinomatosis is common in the evolution of this type of cancer, as well as increased levels of ACE. This peritoneal carcinomatosis is often underestimated, this being due to low sensitivity detection means. In recent years, it has been shown that peritoneal carcinomatosis surgery as complete as possible associated with an intraperitoneal chemotherapy gave better results but still failures associated with the presence of microscopic residual tumors. The use of SGM -101 (developped by SURGIMAB SAS) allows surgeons to detect tumor nodules of small size very easily, in real-time, during surgery (shown in animals).

NCT ID: NCT02759588 Completed - Ovarian Cancer Clinical Trials

GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer

Start date: May 2016
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine if GL-ONC1 oncolytic immunotherapy is well tolerated with anti-tumor activity in patients diagnosed with recurrent or refractory ovarian cancer and peritoneal carcinomatosis.

NCT ID: NCT02658214 Completed - Clinical trials for Esophageal Squamous Cell Carcinoma

Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors

Start date: April 28, 2016
Phase: Phase 1
Study type: Interventional

Durvalumab and Tremelimumab in combination with first-line chemotherapy in the following indications: Ovarian/peritoneal/fallopian tube cancer, SCCHN, TNBC, SCLC and gastric/GEJ cancer, PDAC, ESCC.